Gilead Sciences CEO Daniel O'Day Files Form 144 to Sell $7.6M in Common Stock

Executive Summary

On October 30, 2026, Daniel O'Day, Director and Officer (Chairman and CEO) of Gilead Sciences, Inc. ($GILD), filed a Form 144 disclosing a proposed sale of 45,881 shares of common stock with an aggregate market value of approximately $7,598,352.41. The proposed sale is executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026.

Transaction Breakdown

• Securities to be Sold: 45,881 common shares
• Aggregate Market Value: $7,598,352.41 (~$165.61 per share)
• Source of Shares:
  • 15,881 shares acquired on October 30, 2026 via cash exercise of stock options
  • 30,000 shares acquired on February 4, 2025 via performance stock units (PSUs)
• Executing Broker: Morgan Stanley Smith Barney LLC Executive Financial Services

Historical Context & Rule 10b5-1 Trading

The sale is scheduled under a Rule 10b5-1 trading plan established on February 25, 2026, well in advance of the transaction date. Historical sales disclosed in the filing show a regular cadence of sales under the same plan:

• October 1, 2026: 15,000 shares for gross proceeds of $2,218,507.50
• September 1, 2026: 15,000 shares for gross proceeds of $2,229,592.50
• August 3, 2026: 15,000 shares for gross proceeds of $1,954,693.80

Market Impact & Significance

The filing represents a routine, scheduled liquidation of equity awards under an established 10b5-1 plan. Given the pre-scheduled nature of the transactions and the relatively modest size compared to Gilead's total outstanding shares (1,240,338,614 shares), trading significance is categorized as Medium.